Germany· DE-A57-224fa7201ed757eb
Amphotericin B Cheplapharm
A medicinal product containing amphotericin b, registered in Germany by Cheplapharm Arzneimittel Gmbh.
Checked against EMA Article 57 (European Union) on
Informational only — not a medical device.
The record
At a glance
EMA Article 57 (European Union)- Active substance
- Amphotericin B
- Manufacturer
- Cheplapharm Arzneimittel Gmbh
- Country
- Germany (DE)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- EMA Article 57 (European Union)
- Last checked
- September 30, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Amphotericin b in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomAbelcet 100mg/20ml concentrate for dispersion for infusion vialsTeva UK Ltd
- FinlandAbelcetTeva Pharma B.V.
- SwitzerlandAmbisome
- United StatesAmBisomeAstellas Pharma US, Inc.
- CzechiaABELCET LIPID COMPLEXTeva Pharmaceuticals CR, s.r.o., Praha
- PolandAbelcetTeva Pharmaceuticals Polska Sp. z o.o.
- FranceAMBISOME liposomal 50 mg, poudre pour dispersion pour perfusionGILEAD SCIENCES
- NetherlandsAmBisome liposomale amfotericine B 50 mg, poeder voor dispersie voor infusieGilead Sciences Ireland UC
Authorised across Europe · EMA
The same active substance is authorised in 27 EEA countries. Names it is sold under:
- Austria · Ambisome Liposomal, Ampho-Moronal
- Belgium · Ambisome Liposomales, Amfotericine B Liposomaal Tillomed
- Bulgaria · Амфотерицин B Липозомал Тиломед
- Cyprus · Ambisome Liposomal, Amphotericin B Liposomal Tillomed
- Czechia · Abelcet Lipid Complex, Amfotericin B Liposomal Tillomed
- Denmark · Ambisome Liposomal
- Estonia · Amphotericin B Liposomal Tillomed
- Spain · Abelcet Complejo Lipídico, Ambisome Liposomal
- Finland · Ambisome Liposomal, Fungizone
- France · Ambisome Liposomal, Fungizone
- United Kingdom (Northern Ireland) · Amphotericin B Liposomal Gilead, Amphotericin B Liposomal Sun Pharma
- Greece · Ambisome Liposomal
- Hungary · Abelcet, Ambisome Liposzómás
- Ireland · Ambisome liposomal, Amphotericin B Liposomal Tillomed
- Iceland · Ambisome Liposomal
- Italy · Ambisome Liposomiale, Fungizone
- Luxembourg · Abelcet Lipid Complex, Ambisome Liposomales
- Latvia · Ambisome liposomāls, Amphotericin B Tillomed
- Malta · Ambisome Liposomal
- Netherlands · Ambisome liposomale, Amfotericine B Liposomaal Tillomed
- Norway · Ambisome Liposomal
- Poland · Abelcet, Ambisome Liposomal
- Portugal · Abelcet, Ambisome Lipossomal
- Romania · Ambisome liposomal, Amfotericină B Lipozomală Tillomed
- Sweden · Ambisome Liposomal, Amphotericin B Liposomal Tillomed
- Slovenia · Ambisome Liposomal, Amfotericin B Liposomal Tillomed
- Slovakia · Abelcet Lipid Complex
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b633b4c2-932b-416b-94ad-1f79569c8d8a GET /v1/drugs/b633b4c2-932b-416b-94ad-1f79569c8d8a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"pzn": null,
"route": "Intravenous Use",
"source": "ema_art57_de",
"ma_number": null,
"substance": "Amphotericin B",
"atc_from_source": null,
"authorisation_country": "Germany"
}See everything about amphotericin b.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.